What is Synbio Technologies?
Synbio Technologies operates at the forefront of synthetic biology, offering a comprehensive suite of services essential for modern biological research and development. Their expertise spans gene synthesis, protein expression, and gene editing, providing researchers worldwide with high-precision, cost-effective custom synthetic biology products designed to meet stringent manufacturing standards. The company's extensive portfolio includes oligonucleotide diagnostics, recombinant collagen solutions, and innovative AI-enhanced protein production technologies, positioning them as a vital partner for scientific advancement and discovery.
How much funding has Synbio Technologies raised?
Synbio Technologies has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Synbio Technologies?
The substantial late-stage funding and recent strategic investment signal a pivotal moment for Synbio Technologies. This capital infusion is expected to accelerate the company's growth initiatives, potentially enabling expansion into new markets, further development of their AI-driven protein production capabilities, and enhancement of their custom solutions for the global research community. The company is poised to solidify its leadership in synthetic biology, facilitating further breakthroughs across various scientific disciplines.
See full Synbio Technologies company page
